- Money Masters
- Posts
- 3 Stocks to Buy and 3 to Sell Now
3 Stocks to Buy and 3 to Sell Now
In today's market, savvy investors know that spotting...
Kenny
November 08, 2024
In partnership with
The NEXT Trillion Dollar Company?
This company just signed a MASSIVE deal with Apple.
It gets their AI tech in Apple’s iPhones and iMacs until 2040!
But it goes beyond that.
The company is getting its tech into products by Nvidia, Google, and Samsung too.
Its AI tech is so crucial…
Nvidia is actually buying up the stock too.
They’ve invested more in this one company than any other… nearly $150 million.
Is this stock the next Nvidia… which has gone up 81,700% over the last 20 years?
THE MONEY IDEA💡
3 Stocks to Buy and 3 to Sell Now
Welcome to Money Masters!
In today's market, savvy investors know that spotting undervalued gems and identifying overhyped stocks is key to maximizing returns. With that in mind, we’re highlighting three stocks primed for growth and three that may be better to let go. By evaluating each company’s valuation, growth potential, and industry position, we aim to guide you toward smart, strategic decisions.
Let’s dive in.
THE MONEY IDEA💡
3 Stocks to Buy
Value Pick: Rated 5 stars, FMC is trading at a substantial 43% discount to fair value.
Market Edge: With patented crop protection products, FMC holds pricing power and a robust economic moat.
Revenue Boost: Management projects a 19% revenue increase in the next quarter, driven by strong product performance.
Sector Recovery: Inventory destocking trends appear temporary, positioning FMC for growth in 2025.
Investor Takeaway: At a significant discount, FMC offers compelling growth potential in the agricultural sector.
Discounted Buy: Currently undervalued by 28%, Zimmer Biomet offers a wide economic moat and long-term potential.
Growing Demand: Favorable demographics and an aging population drive demand for joint replacement products.
Switching Costs: Orthopedic surgeons face high switching costs, ensuring stable demand for Zimmer’s instruments.
GLP-1 Drug Concerns Overblown: Weight-loss drugs aren’t expected to impact joint replacement demand significantly.
Attractive Valuation: Zimmer trades at a P/E ratio below 14x with an expected 10% CAGR in earnings, making it an excellent value pick.
Undervalued Opportunity: Trading at a 22% discount to fair value, Alphabet presents an attractive entry for long-term investors.
Moat Strength: Google’s broad reach in digital advertising, search, and AI places it among the most competitive tech giants.
AI Momentum: Alphabet benefits significantly from AI innovations, enhancing ad effectiveness and user engagement.
Cloud Success: Google Cloud’s growth hit 35% YoY, providing a steady revenue boost.
Valuation Insights: With a projected 17% compound annual growth rate (CAGR) for the next five years, Alphabet looks attractively priced at current levels.
The Content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
THE MONEY IDEA💡
3 Stocks to Sell
Stock Surge: Up around 180% in the last year, Palantir has been on a tear, fueled by AI enthusiasm.
Valuation Premium: Trades at a 120% premium to fair value, pricing in lofty growth expectations.
Growth Potential: Positive outlook in AI-related business solutions, but its valuation may be excessive.
Financial Metrics: Projected to triple revenue over five years with a 22% CAGR.
High P/E: With a 2028 P/E over 50x, Palantir’s price assumes significant long-term growth—investors should approach with caution.
Valuation Check: ARM trades at a high premium, sparking concerns despite positive growth prospects.
Revenue Growth: Expected CAGR of 20%, targeting substantial gains over the next five years.
Margin Expansion: Operating margins projected to rise from 28% to over 40% in 2028.
Competitive Pressure: High multiples mean ARM must continue delivering exceptional results.
High Hopes in AI: While ARM is benefiting from the AI boom, its valuation leaves little room for error.
Overvalued Status: Novo trades at a 30% premium, rated as overvalued by analysts.
Drug Demand: Ozempic and similar drugs drive demand, though competition is growing.
Revenue Drivers: Double-digit growth is expected from its diabetes and weight-loss drugs.
High Stakes in R&D: Investors are focused on potential new uses for GLP-1 drugs.
Market Position: As competition intensifies, Novo’s valuation could face pressure if growth expectations falter.
The Content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NEWSLETTER CORNER🗞️
Subscribe To Our Friends!
QUOTE CORNER📄
Quote of The Week
You are now closer to money mastery!🎉
What did you think of this week’s newsletter?
Did you like it? How can we improve?
Hit reply and share some feedback!
Reply